Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-203a-3p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

New RDM0040H 96 wells (1 kit)
PubMed Product Details
Technical Data


miREIA – miRNA enzyme immunoassay


Serum, Whole blood, Tissue

Sample Requirements

10 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

25 – 0.78 amol/μl

Limit of Detection

0.26 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 8.7%

Inter-assay (Run-to-Run)

n = 5,
CV = 8.1%

Spiking Recovery


Dilution Linearity



Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.

Product Manual: miREIA - microRNA enzyme immunoassay




  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-203a-3p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic



MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miR-203a has been found to be a crucial regulator involved in various malignancies, such as gastric cancer (GC), nasopharyngeal carcinoma (NPC), breast cancer, lung cancer, liver cancer, and colorectal cancer (CRC). The expression of miR-203a-3p was decreased in NPC tissues and cell lines in comparison with normal nasopharyngeal tissues and cell line. miR-203a-3p suppresses tumor growth and metastasis through targeting LASP1 in NPC. miR-203a-3p was also down-regulated in non-small cell lung cancer (NSCLC) tissues and cells compared with normal tissues and cells. miR-203a-3p together with other three miRNAs (miR-7-5p, miR-145-5p and miR-192-5p) were reported to be down-regulated in hepatocellular carcinoma (HCC), and could inhibit HCC progression by modulating expression of multiple target genes. Decrease of TFF3 was associated with increase of miR-203a-3p in plasma of HCC patients and these molecules displayed potent predictive power for HCC diagnosis. It was published that IGF-1R is a direct co-target of miR-99b-5p/203a-3p that may function as tumor suppressive miRNAs by negatively regulating IGF-1R expression in GC cells. In another study, significant downregulation and proximal promoter methylation of miR-203a and miR-203b in gastric cardia adenocarcinoma (GCA) tissues was found. The methylation status of miR-203a and miR-203b in tumor tissues was negatively correlated with their expression level. GCA patients in stage III and IV with reduced expression or hypermethylation of miR-203a demonstrated poor survival. In conclusion, miR-203a and miR-203b may function as tumor suppressive miRNAs, and reactivation of miR-203a may have therapeutic potential GCA patients. miR-203a-3p also promotes colorectal cancer cell proliferation, colony formation and migration and invasion which suggests that miR-203a-3p may be a novel molecular therapeutic target for CRC.

Up-regulation of miR-203a-3p might inhibit pathological retinal angiogenesis in proliferative diabetic retinopathy (PDR). Expression levels of miR-335-5p, miR-485-5p, miR-16-5p, miR-150-5p, miR-34a-5p, and miR-203a-3p were significantly increased in PBMCs from patients with rheumatoid arthritis (RA) compared with healthy controls.

Summary References (14)

References to miR-203a-3p

  • Yang H, Wang L, Tang X, Bai W: miR-203a suppresses cell proliferation by targeting E2F transcription factor 3 in human gastric cancer. Oncol Lett 2017; 14: 7687-7690.
  • Meng, R., et al. "miR-129-5p suppresses breast cancer proliferation by targeting CBX4." Neoplasma 65.4 (2018): 572.
  • Xiao, Guodong, et al. "MiR-129 blocks estrogen induction of NOTCH signaling activity in breast cancer stem-like cells." Oncotarget 8.61 (2017): 103261.
  • Wu, Qiong, et al. "LncRNA MALAT1 induces colon cancer development by regulating miR‐129‐5p/HMGB1 axis." Journal of cellular physiology 233.9 (2018): 6750-6757.
  • Liu, Ke, et al. "MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142–3p and miR-129–5p." Cell cycle 16.6 (2017): 578-587.
  • Zhang, Yongzhou, et al. "miRNA 129 5p suppresses cell proliferation and invasion in lung cancer by targeting microspherule protein 1, E cadherin and vimentin." Oncology letters 12.6 (2016): 5163-5169.
  • Han, Han, et al. "microRNA-129-5p, a c-Myc negative target, affects hepatocellular carcinoma progression by blocking the Warburg effect." Journal of molecular cell biology 8.5 (2016): 400-410.
  • Gu, Xuhui, et al. "MicroRNA-129-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting DNMT3A." American journal of translational research 10.9 (2018): 2834.
  • Yan, Lei, et al. "MiR-129-5p influences the progression of gastric cancer cells through interacting with SPOCK1." Tumor Biology 39.6 (2017): 1010428317706916.
  • Liu, Qi, et al. "MiR-129-5p functions as a tumor suppressor in gastric cancer progression through targeting ADAM9." Biomedicine & Pharmacotherapy 105 (2018): 420-427.
  • Chen, Di, et al. "MicroRNA-129-5p regulates glycolysis and cell proliferation by targeting the glucose transporter SLC2A3 in gastric cancer cells." Frontiers in pharmacology 9 (2018).
  • Patrick, Ellis, et al. "Dissecting the role of non-coding RNAs in the accumulation of amyloid and tau neuropathologies in Alzheimer’s disease." Molecular neurodegeneration 12.1 (2017): 51.
  • Trujillo-Gonzalez, Isis, et al. "MicroRNA-129-5p is regulated by choline availability and controls EGF receptor synthesis and neurogenesis in the cerebral cortex." The FASEB Journal 33.3 (2018): 3601-3612.
  • Ramachandran, Sweta, et al. "Plasma microvesicle analysis identifies microRNA 129-5p as a biomarker of heart failure in univentricular heart disease." PloS one 12.8 (2017): e0183624.
Related Products Docs